CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.310
-0.201 (-13.30%)
At close: Sep 26, 2025, 4:00 PM EDT
1.319
+0.009 (0.70%)
After-hours: Sep 26, 2025, 7:58 PM EDT
CASI Pharmaceuticals Revenue
CASI Pharmaceuticals had revenue of $4.18M in the quarter ending June 30, 2025, with 4.93% growth. This brings the company's revenue in the last twelve months to $31.56M, up 36.64% year-over-year. In the year 2024, CASI Pharmaceuticals had annual revenue of $28.54M, down -15.77%.
Revenue (ttm)
$31.56M
Revenue Growth
+36.64%
P/S Ratio
0.68
Revenue / Employee
$135,468
Employees
233
Market Cap
20.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CASI News
- 1 day ago - CASI Pharmaceuticals Appoints James Huang to Board of Directors - Accesswire
- 19 days ago - CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study - Accesswire
- 24 days ago - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - Accesswire
- 25 days ago - CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors - Accesswire
- 4 weeks ago - CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results - Accesswire
- 4 weeks ago - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 - Accesswire
- 7 weeks ago - CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) - Accesswire
- 2 months ago - CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - Accesswire